University Medical Center Groningen
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1614-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- https://www.umcg.nl
Clinical Trials
927
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (454 trials with phase data)• Click on a phase to view related trials
Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW
- Conditions
- Esophageal Cancer
- Interventions
- Device: Spectroscopy systemDrug: Nivolumab-800CWDrug: Durvalumab-680LT
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 15
- Registration Number
- NCT07196384
Fatigue in MS: From Invisible to Measurable
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 40
- Registration Number
- NCT07182903
FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 180
- Registration Number
- NCT07181135
Virtual Reality Assisted Schema Therapy
- Conditions
- Healthy Participants
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT07171736
- Locations
- 🇳🇱
UMCG, Groningen, Provincie Groningen, Netherlands
Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection
- Conditions
- Esophageal CarcinomaGastric Carcinoma
- Interventions
- Drug: Indocyanine Green (IC-Green)Diagnostic Test: Fluorescence guided identification using indocyanine green
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 10
- Registration Number
- NCT07108855
- Locations
- 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands
- Prev
- 1
- 2
- 3
- 4
- 5
- 118
- Next
News
Team Sports Enhance Cognitive Development and Academic Success in Children, Studies Show
Children participating in team sports like soccer and volleyball demonstrate superior executive function skills compared to those in individual sports or no sports, according to a Dutch longitudinal study published in JAMA Network Open.
Tirzepatide Shows Promising Renal Benefits in Type 2 Diabetes Patients Through SURPASS Trials Analysis
Post hoc analysis of SURPASS trials reveals tirzepatide significantly reduced urine albumin-to-creatinine ratio by up to 26.3% compared to control groups in type 2 diabetes patients.
Brexu-Cel Demonstrates High Response Rates in BTK Inhibitor-Naive Relapsed/Refractory MCL
Brexucabtagene autoleucel (brexu-cel) shows a 91% overall response rate (ORR) in patients with relapsed/refractory mantle cell lymphoma (MCL) who are BTK inhibitor-naive.
Ozempic Shows Promise in Curbing Kidney Disease in Obese Individuals Without Diabetes
Semaglutide, the active agent in Ozempic and Wegovy, demonstrates a significant 52% reduction in kidney damage among obese individuals without diabetes.
ASN Kidney Week 2024: Novel Clinical Trials Highlight Advances in Kidney Disease Treatment
Finerenone shows similar long-term kidney function patterns to placebo in heart failure patients, while reducing protein leakage, suggesting potential benefits in specific outcomes.